Sirius Investors
301.37
0.72%Today
Market Cap
162.05B
Volume
1.53M
52W High
340.89
52W Low
253.30

No historical price data available

No price history data available for the selected time period.

Try selecting a different time range.

Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Company Information

CEO
Robert A. Bradway
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
28000

Contact Information

Address
One Amgen Center Drive
Country
US

Investment Analysis & Insights

Key Investment Highlights

  • Market Position: Healthcare leader with 162.05B market capitalization
  • Trading Volume: 1.53M shares traded today
  • Price Range: 52-week range of $253.30 - $340.89
  • Exchange: Listed on NASDAQ Global Select

Financial Metrics

P/E Ratio:27.50
EPS:$10.96
Beta:0.48
Avg Volume:2.62M

Market Analysis for Amgen Inc.

Amgen Inc. (AMGN) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 162.05B, the company represents a significant player in its market. The stock is currently trading at $301.37 with a negativedaily change of 0.72%.

The company's 28000 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 27.50, beta of 0.48, and 52-week price range from $253.30 to $340.89when evaluating investment opportunities.

Why Invest in Amgen Inc.?

Strengths
  • • Established market presence in Healthcare
  • • Strong financial metrics and market position
  • • Listed on major exchange (NASDAQ Global Select)
  • • Experienced leadership under Robert A. Bradway
Investment Considerations
  • • Monitor sector-specific market trends
  • • Track quarterly earnings performance
  • • Consider market volatility and beta
  • • Evaluate long-term growth potential
Amgen Inc. (AMGN) Stock Analysis | Sirius Investors